Human Testing of Johnson & Johnson Coronavirus Vaccine to
Begin By September Johnson & Johnson said Monday that its
experimental vaccine could be available for
emergency use authorization by early 2021. The company said it has committed more than
$1 billion to co-fund the vaccine research, with the federal Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services. Shares of Johnson & Johnson rose more than 4%
in premarket trading following the announcement. Johnson & Johnson is also increasing its
manufacturing capacity with a new location in the U.S., and expansions to existing sites in other countries
to potentially distribute the vaccine quickly. Alex Gorsky, Johnson & Johnson CEO, via CNBC Alex Gorsky, via CNBC